The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 22, 2019

Filed:

Nov. 28, 2016
Applicants:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Yongxin Han, Boston, MA (US);

Phieng Siliphaivanh, Boston, MA (US);

Kerrie Spencer, Boston, MA (US);

Satyanarayana Tummanapalli, Albany, NY (US);

Inventors:

Yongxin Han, Needham, MA (US);

Satyanarayana Tummanapalli, Hyderabad, IN;

Phieng Siliphaivanh, Newton, MA (US);

Kerrie Spencer, Woonsocket, RI (US);

Assignee:

Merch Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/35 (2006.01); A61P 3/10 (2006.01); C07D 311/22 (2006.01); C07D 311/58 (2006.01); C07D 405/14 (2006.01); C07D 417/14 (2006.01);
U.S. Cl.
CPC ...
C07D 417/14 (2013.01); A61K 31/35 (2013.01); A61P 3/10 (2018.01); C07D 311/22 (2013.01); C07D 311/58 (2013.01); C07D 405/14 (2013.01);
Abstract

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene Breceptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene Breceptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, Non-alcoholic fatty liver disease/nonalcoholic steatohepatitis, metabolic syndrome, atherosclerosis, and cancer.


Find Patent Forward Citations

Loading…